Research Institute for Diseases of Old Age, Graduate School of Medicine, Juntendo University, Tokyo, Japan; Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan; Training Program of Leaders for Integrated Medical System for Fruitful Healthy-Longevity Society (LIMS), Kyoto University Graduate School of Medicine, Kyoto, Japan.
Lancet Neurol. 2015 Mar;14(3):274-82. doi: 10.1016/S1474-4422(14)70266-2. Epub 2015 Feb 4.
Identification of causative genes in mendelian forms of Parkinson's disease is valuable for understanding the cause of the disease. We did genetic studies in a Japanese family with autosomal dominant Parkinson's disease to identify novel causative genes.
We did a genome-wide linkage analysis on eight affected and five unaffected individuals from a family with autosomal dominant Parkinson's disease (family A). Subsequently, we did exome sequencing on three patients and whole-genome sequencing on one patient in family A. Variants were validated by Sanger sequencing in samples from patients with autosomal dominant Parkinson's disease, patients with sporadic Parkinson's disease, and controls. Participants were identified from the DNA bank of the Comprehensive Genetic Study on Parkinson's Disease and Related Disorders (Juntendo University School of Medicine, Tokyo, Japan) and were classified according to clinical information obtained by neurologists. Splicing abnormalities of CHCHD2 mutants were analysed in SH-SY5Y cells. We used the Fisher's exact test to calculate the significance of allele frequencies between patients with sporadic Parkinson's disease and unaffected controls, and we calculated odds ratios and 95% CIs of minor alleles.
We identified a missense mutation (CHCHD2, 182C>T, Thr61Ile) in family A by next-generation sequencing. We obtained samples from a further 340 index patients with autosomal dominant Parkinson's disease, 517 patients with sporadic Parkinson's disease, and 559 controls. Three CHCHD2 mutations in four of 341 index cases from independent families with autosomal dominant Parkinson's disease were detected by CHCHD2 mutation screening: 182C>T (Thr61Ile), 434G>A (Arg145Gln), and 300+5G>A. Two single nucleotide variants (-9T>G and 5C>T) in CHCHD2 were confirmed to have different frequencies between sporadic Parkinson's disease and controls, with odds ratios of 2·51 (95% CI 1·48-4·24; p=0·0004) and 4·69 (1·59-13·83, p=0·0025), respectively. One single nucleotide polymorphism (rs816411) was found in CHCHD2 from a previously reported genome-wide association study; however, there was no significant difference in its frequency between patients with Parkinson's disease and controls in a previously reported genome-wide association study (odds ratio 1·17, 95% CI 0·96-1·19; p=0·22). In SH-SY5Y cells, the 300+5G>A mutation but not the other two mutations caused exon 2 skipping.
CHCHD2 mutations are associated with, and might be a cause of, autosomal dominant Parkinson's disease. Further genetic studies in other populations are needed to confirm the pathogenicity of CHCHD2 mutations in autosomal dominant Parkinson's disease and susceptibility for sporadic Parkinson's disease, and further functional studies are needed to understand how mutant CHCHD2 might play a part in the pathophysiology of Parkinson's disease.
Japan Society for the Promotion of Science; Japanese Ministry of Education, Culture, Sports, Science and Technology; Japanese Ministry of Health, Labour and Welfare; Takeda Scientific Foundation; Cell Science Research Foundation; and Nakajima Foundation.
鉴定孟德尔形式帕金森病的致病基因对于了解疾病的病因具有重要意义。我们对一个常染色体显性遗传帕金森病的日本家族进行了遗传研究,以鉴定新的致病基因。
我们对一个常染色体显性遗传帕金森病(家族 A)的 8 名受影响者和 5 名未受影响者进行了全基因组连锁分析。随后,我们对家族 A 的 3 名患者进行了外显子组测序,对 1 名患者进行了全基因组测序。通过对来自常染色体显性遗传帕金森病患者、散发性帕金森病患者和对照者的样本进行 Sanger 测序,对变异进行了验证。参与者来自综合帕金森病及相关疾病遗传研究(日本东京顺天堂大学医学院)的 DNA 库,并根据神经病学家获得的临床信息进行了分类。分析了 CHCHD2 突变体的剪接异常情况在 SH-SY5Y 细胞中。我们使用 Fisher 精确检验计算散发性帕金森病患者与未受影响对照者之间等位基因频率的显著性,计算了小等位基因的比值比和 95%置信区间。
通过下一代测序,我们在家族 A 中鉴定出一个错义突变(CHCHD2,182C>T,Thr61Ile)。我们从另外 340 名常染色体显性遗传帕金森病的索引患者、517 名散发性帕金森病患者和 559 名对照者中获得了样本。通过 CHCHD2 突变筛查,在四个独立的常染色体显性遗传帕金森病家族的 341 名索引病例中的三个中检测到三个 CHCHD2 突变:182C>T(Thr61Ile)、434G>A(Arg145Gln)和 300+5G>A。在 CHCHD2 中,两个单核苷酸变异(-9T>G 和 5C>T)在散发性帕金森病和对照组之间的频率被证实存在差异,比值比分别为 2.51(95%CI 1.48-4.24;p=0.0004)和 4.69(1.59-13.83,p=0.0025)。在以前的全基因组关联研究中发现了 CHCHD2 中的一个单核苷酸多态性(rs816411);然而,在以前的全基因组关联研究中,帕金森病患者和对照组之间其频率没有显著差异(比值比 1.17,95%CI 0.96-1.19;p=0.22)。在 SH-SY5Y 细胞中,300+5G>A 突变但不是其他两个突变导致外显子 2 跳跃。
CHCHD2 突变与常染色体显性遗传帕金森病有关,可能是其病因。需要在其他人群中进行进一步的遗传研究,以确认 CHCHD2 突变在常染色体显性遗传帕金森病中的致病性和散发性帕金森病的易感性,并进一步进行功能研究,以了解突变型 CHCHD2 如何在帕金森病的病理生理学中发挥作用。
日本学术振兴会;日本文部科学省;日本厚生劳动省;武田科学基金会;细胞科学研究基金会;中岛基金会。